hepatic fat: the version I wish someone had shown me in week 1
hepatic fat: the version I wish someone had shown me in week 1. Full detail below, and I have tried to keep the editorialising out of it.
Bought small because the evidence base is early. That is the only defensible position I could construct.
Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Left up. It reads the paper carefully and is explicit about the population.
phase 2 in liver disease is a different evidence question from weight
That figure is from the obesity programme, and this thread is about the hepatic one.
phase 2 in liver disease is a different evidence question from weight
vikram_mbeki is right that biopsy and imaging endpoints are not interchangeable.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis wit
Disagreeing with this bit: that number comes from a different programme with a different population.